Necrotizing fasciitis associated with sorafenib treatment
Ho Won Kang,
Seok-Joong Yun,
Wun-Jae Kim
Affiliations
Ho Won Kang
Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea
Seok-Joong Yun
Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea; Corresponding author at: Department of Urology, College of Medicine and Institute for Tumor Research, Chungbuk National University, 776 1sunhwan-ro, Seowon-gu, Cheonju 28644, South Korea.
Wun-Jae Kim
Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea; Department of Urology, Chungbuk National University Hospital, Cheongju, South Korea
We present here a case of extensive necrotizing fasciitis during sorafenib treatment in a patient with HBV-related hepatocellular carcinoma. Despite emergent extensive surgical debridement, the patient's clinical status progressive worsened until interruption of sorafenib therapy. The patient was successfully treated with temporal interruption of sorafenib therapy. To our knowledge, this is the first case report of sorafenib-associated necrotizing fasciitis. Given the life-threatening nature of the infection and the necessity for urgent intervention, clinicians should be aware of this possible adverse effect of tyrosine kinase inhibitors. Keywords: Necrotizing fasciitis, Adverse drug reaction, Tyrosine kinase inhibitors, Hepatocellular carcinoma
